| Authors: |
Safgren SL; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Olson RLO; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Vrabel AM; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Almada LL; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Marks DL; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Hernandez-Alvarado N; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA., Gaspar-Maia A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Fernandez-Zapico ME; Schulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA. Electronic address: fernandez-zapico.martin@mayo.edu. |